Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × Palliative Care × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 213 Carboplatin 119 Nivolumab 107 Gemcitabine 107 Paclitaxel 105 Cisplatin 87 Bevacizumab 85 Cyclophosphamide 77 Dexamethasone 66 Docetaxel 62 Injections 61 Pemetrexed 59 Capecitabine 55 atezolizumab 54 Fluorouracil 54 Rituximab 53 Cetuximab 52 130-nm albumin-bound paclitaxel 52 Oxaliplatin 47 Leucovorin 43 Lenalidomide 41 Ipilimumab 39 venetoclax 37 Azacitidine 35 Prednisone 33 fludarabine 32 Trastuzumab 32 Fulvestrant 32 Albumin-Bound Paclitaxel 32 Irinotecan 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07467863 2026-03-12

DUO-NK-NSCLC

Beijing Biotech

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡